129 related articles for article (PubMed ID: 8258200)
1. Inhibitory effects of anticancer drugs on dextromethorphan-O-demethylase activity in human liver microsomes.
Le Guellec C; Lacarelle B; Catalin J; Durand A
Cancer Chemother Pharmacol; 1993; 32(6):491-5. PubMed ID: 8258200
[TBL] [Abstract][Full Text] [Related]
2. The effect of cimetidine on dextromethorphan O-demethylase activity of human liver microsomes and recombinant CYP2D6.
Madeira M; Levine M; Chang TK; Mirfazaelian A; Bellward GD
Drug Metab Dispos; 2004 Apr; 32(4):460-7. PubMed ID: 16680870
[TBL] [Abstract][Full Text] [Related]
3. The potential for CYP2D6 inhibition screening using a novel scintillation proximity assay-based approach.
Delaporte E; Slaughter DE; Egan MA; Gatto GJ; Santos A; Shelley J; Price E; Howells L; Dean DC; Rodrigues AD
J Biomol Screen; 2001 Aug; 6(4):225-31. PubMed ID: 11689122
[TBL] [Abstract][Full Text] [Related]
4. Selective inhibition of major drug metabolizing cytochrome P450 isozymes in human liver microsomes by carbon monoxide.
Leemann T; Bonnabry P; Dayer P
Life Sci; 1994; 54(14):951-6. PubMed ID: 8139385
[TBL] [Abstract][Full Text] [Related]
5. High-performance liquid chromatographic assays for bufuralol 1'-hydroxylase, debrisoquine 4-hydroxylase, and dextromethorphan O-demethylase in microsomes and purified cytochrome P-450 isozymes of human liver.
Kronbach T; Mathys D; Gut J; Catin T; Meyer UA
Anal Biochem; 1987 Apr; 162(1):24-32. PubMed ID: 3605590
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation.
Schmider J; Greenblatt DJ; von Moltke LL; Harmatz JS; Shader RI
Br J Clin Pharmacol; 1996 Apr; 41(4):339-43. PubMed ID: 8730981
[TBL] [Abstract][Full Text] [Related]
7. The role of CYP2D6 in primary and secondary oxidative metabolism of dextromethorphan: in vitro studies using human liver microsomes.
Kerry NL; Somogyi AA; Bochner F; Mikus G
Br J Clin Pharmacol; 1994 Sep; 38(3):243-8. PubMed ID: 7826826
[TBL] [Abstract][Full Text] [Related]
8. CYP2D6- and CYP3A-dependent metabolism of dextromethorphan in humans.
Jacqz-Aigrain E; Funck-Brentano C; Cresteil T
Pharmacogenetics; 1993 Aug; 3(4):197-204. PubMed ID: 8220439
[TBL] [Abstract][Full Text] [Related]
9. The role of lipophilicity in the inhibition of polymorphic cytochrome P450IID6 oxidation by beta-blocking agents in vitro.
Ferrari S; Leemann T; Dayer P
Life Sci; 1991; 48(23):2259-65. PubMed ID: 1675413
[TBL] [Abstract][Full Text] [Related]
10. The inhibitory effect of amiodarone and desethylamiodarone on dextromethorphan O-demethylation in human and rat liver microsomes.
Jaruratanasirikul S; Hortiwakul R
J Pharm Pharmacol; 1994 Nov; 46(11):933-5. PubMed ID: 7897605
[TBL] [Abstract][Full Text] [Related]
11. Potent inhibition of yeast-expressed CYP2D6 by dihydroquinidine, quinidine, and its metabolites.
Ching MS; Blake CL; Ghabrial H; Ellis SW; Lennard MS; Tucker GT; Smallwood RA
Biochem Pharmacol; 1995 Sep; 50(6):833-7. PubMed ID: 7575645
[TBL] [Abstract][Full Text] [Related]
12. The in vitro interaction of dexmedetomidine with human liver microsomal cytochrome P4502D6 (CYP2D6).
Rodrigues AD; Roberts EM
Drug Metab Dispos; 1997 May; 25(5):651-5. PubMed ID: 9152607
[TBL] [Abstract][Full Text] [Related]
13. Dextromethorphan O-demethylation in liver microsomes as a prototype reaction to monitor cytochrome P-450 db1 activity.
Dayer P; Leemann T; Striberni R
Clin Pharmacol Ther; 1989 Jan; 45(1):34-40. PubMed ID: 2910636
[TBL] [Abstract][Full Text] [Related]
14. Cytochrome P450IID subfamily in non-human primates. Catalytical and immunological characterization.
Jacqz-Aigrain E; Gueguen M; Zanger UM; Robieux I; Alvarez F
Biochem Pharmacol; 1991 Jun; 41(11):1657-63. PubMed ID: 2043154
[TBL] [Abstract][Full Text] [Related]
15. Inhibitory studies of mexiletine and dextromethorphan oxidation in human liver microsomes.
Broly F; Libersa C; Lhermitte M; Dupuis B
Biochem Pharmacol; 1990 Mar; 39(6):1045-53. PubMed ID: 2322292
[TBL] [Abstract][Full Text] [Related]
16. Methoxyphenamine O-demethylase and 5-hydroxylase: a GLC-ECD assay to study their activities and their inhibition by debrisoquine and sparteine.
Hawes EM; Roy SD; McKay G; Midha KK
Pharmacol Ther; 1987; 33(1):73-7. PubMed ID: 3628478
[TBL] [Abstract][Full Text] [Related]
17. Identification of human liver cytochrome P450 enzymes that metabolize the nonsedating antihistamine loratadine. Formation of descarboethoxyloratadine by CYP3A4 and CYP2D6.
Yumibe N; Huie K; Chen KJ; Snow M; Clement RP; Cayen MN
Biochem Pharmacol; 1996 Jan; 51(2):165-72. PubMed ID: 8615885
[TBL] [Abstract][Full Text] [Related]
18. Cannabidiol, a major phytocannabinoid, as a potent atypical inhibitor for CYP2D6.
Yamaori S; Okamoto Y; Yamamoto I; Watanabe K
Drug Metab Dispos; 2011 Nov; 39(11):2049-56. PubMed ID: 21821735
[TBL] [Abstract][Full Text] [Related]
19. Human liver microsomal cytochrome P450 3A isozymes mediated vindesine biotransformation. Metabolic drug interactions.
Zhou XJ; Zhou-Pan XR; Gauthier T; Placidi M; Maurel P; Rahmani R
Biochem Pharmacol; 1993 Feb; 45(4):853-61. PubMed ID: 8452560
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of human cytochrome P450 2D6 (CYP2D6) by methadone.
Wu D; Otton SV; Sproule BA; Busto U; Inaba T; Kalow W; Sellers EM
Br J Clin Pharmacol; 1993 Jan; 35(1):30-4. PubMed ID: 8448065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
